Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Oklo Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Oklo Inc trades at $28.48 (market cap $5.91B). The key difference: Oklo Inc is far larger — about 2.1× Dyne Therapeutics Inc. Common Stock's market cap, and Oklo Inc is more actively traded (8,898,651 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Oklo Inc for 33 Days on average.
| DYN | OKLO | |
|---|---|---|
Market Cap | $2.86B | $5.91B |
Volume | 3,341,579 | 8,898,651 |
Sector | Health | Utilities |
52-Week High | $26.78 | $171.56 |
52-Week Low | $14.60 | $29.04 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $2.18B | $3.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
OKLO trades at $31.78, down 1.33% on the day, with a bearish technical signal despite oversold RSI readings. The company shows no revenue in 2025 and a net loss of $105.66 million, with negative profit margins and ROE. Recent news highlights competition in the nuclear sector and OKLO's $1 billion stock sale, while analyst consensus remains strongly bullish with a $78.63 price target.
OKLO presents high-risk, high-reward potential as an early-stage nuclear company. The bullish analyst outlook and strategic project pipeline offer upside, but significant execution risks, cash burn, and competitive pressures require careful consideration. Investor sentiment is mixed amid operational challenges and dilution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
